

3 January 2025

Our Ref: FOI 393

Dear

**Freedom of Information Act 2000
Information in Relation to Inflammatory Diseases Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 25 November 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to the questions you have raised has been provided by the Surgery Elective Maternity and Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Keith McCollum
Information Governance Team

Q1. How many patients were treated with the following drugs from the following departments (for any disease) from the start of July 2024 to the end of Sept 2024?

Please use the latest available 3 months if July to Sept is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			
Etrasimod			
Tofacitinib			
Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Q2. How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of July 2024 to the end of Sept 2024?

Please use the latest available 3 months if July to Sept is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
<i>Ustekinumab (Stelara)</i>			
<i>Ustekinumab (Pyzchiva)</i>			
<i>Ustekinumab (Uzpruvo)</i>			
<i>Ustekinumab (Wezenla)</i>			

A1 & A2. Due to the new digital system, the information that you have requested is not centrally held in a way which is easily extracted. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice.